117 related articles for article (PubMed ID: 37290996)
81. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Swords RT; Coutre S; Maris MB; Zeidner JF; Foran JM; Cruz J; Erba HP; Berdeja JG; Tam W; Vardhanabhuti S; Pawlikowska-Dobler I; Faessel HM; Dash AB; Sedarati F; Dezube BJ; Faller DV; Savona MR
Blood; 2018 Mar; 131(13):1415-1424. PubMed ID: 29348128
[TBL] [Abstract][Full Text] [Related]
82. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
83. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Benton CB; Chien KS; Tefferi A; Rodriguez J; Ravandi F; Daver N; Jabbour E; Jain N; Alvarado Y; Kwari M; Pierce S; Maiti A; Hornbaker M; Santos MA; Martinez S; Siguero M; Zblewski D; Al-Kali A; Hogan WJ; Kantarjian H; Pardanani A; Garcia-Manero G
Hematol Oncol; 2019 Feb; 37(1):96-102. PubMed ID: 30153704
[TBL] [Abstract][Full Text] [Related]
84. [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
Xu J; Xu CG; Liu T; Xiang B; Chang H; He C
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):129-32. PubMed ID: 19292062
[TBL] [Abstract][Full Text] [Related]
85. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
[TBL] [Abstract][Full Text] [Related]
86. Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
Goldsmith SR; Lovell AR; Schroeder MA
Drugs Today (Barc); 2019 Sep; 55(9):545-562. PubMed ID: 31584572
[TBL] [Abstract][Full Text] [Related]
87. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.
Papadopoulos KP; Johnson ML; Lockhart AC; Moore K; Falchook GS; Formenti SC; Naing A; Carvajal RD; Rosen LS; Weiss GJ; Leidner RS; Li J; Paccaly A; Feng M; Stankevich E; Lowy I; Fury MG; Crittenden MR
Clin Cancer Res; 2020 Mar; 26(5):1025-1033. PubMed ID: 31796520
[TBL] [Abstract][Full Text] [Related]
88. Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.
Verstovsek S; Foltz L; Gupta V; Hasserjian R; Manshouri T; Mascarenhas J; Mesa R; Pozdnyakova O; Ritchie E; Veletic I; Gamel K; Hamidi H; Han L; Higgins B; Trunzer K; Uguen M; Wang D; El-Galaly TC; Todorov B; Gotlib J
Haematologica; 2023 Oct; 108(10):2730-2742. PubMed ID: 37165840
[TBL] [Abstract][Full Text] [Related]
89. Vorinostat in solid and hematologic malignancies.
Siegel D; Hussein M; Belani C; Robert F; Galanis E; Richon VM; Garcia-Vargas J; Sanz-Rodriguez C; Rizvi S
J Hematol Oncol; 2009 Jul; 2():31. PubMed ID: 19635146
[TBL] [Abstract][Full Text] [Related]
90. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules.
Banchi M; Cox MC; Bocci G
Cancer Lett; 2024 Jun; 591():216900. PubMed ID: 38636896
[TBL] [Abstract][Full Text] [Related]
91. Deep PIM kinase substrate profiling reveals new rational co-therapeutic strategies for acute myeloid leukemia.
Joglekar T; Chin A; Voskanian-Kordi A; Seungchul B; Raja A; Rege A; Huang W; Kane MA; Laiho M; Webb T; Fan X; Rubenstein M; Bieberich CJ; Li X
Blood Adv; 2024 May; ():. PubMed ID: 38739710
[TBL] [Abstract][Full Text] [Related]
92. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
Yap TA; Daver N; Mahendra M; Zhang J; Kamiya-Matsuoka C; Meric-Bernstam F; Kantarjian HM; Ravandi F; Collins ME; Francesco MED; Dumbrava EE; Fu S; Gao S; Gay JP; Gera S; Han J; Hong DS; Jabbour EJ; Ju Z; Karp DD; Lodi A; Molina JR; Baran N; Naing A; Ohanian M; Pant S; Pemmaraju N; Bose P; Piha-Paul SA; Rodon J; Salguero C; Sasaki K; Singh AK; Subbiah V; Tsimberidou AM; Xu QA; Yilmaz M; Zhang Q; Li Y; Bristow CA; Bhattacharjee MB; Tiziani S; Heffernan TP; Vellano CP; Jones P; Heijnen CJ; Kavelaars A; Marszalek JR; Konopleva M
Nat Med; 2023 Jan; 29(1):115-126. PubMed ID: 36658425
[TBL] [Abstract][Full Text] [Related]
93. The MLL-Menin Interaction is a Therapeutic Vulnerability in
Rasouli M; Blair H; Troester S; Szoltysek K; Cameron R; Ashtiani M; Krippner-Heidenreich A; Grebien F; McGeehan G; Zwaan CM; Heidenreich O
Hemasphere; 2023 Aug; 7(8):e935. PubMed ID: 37520776
[TBL] [Abstract][Full Text] [Related]
94. Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia.
Li X; Zhang J; Liu F; Liu T; Zhang R; Chen Y; Guo Y; Fang Y; Xu X; Pui CH; Zhu X
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):660-666. PubMed ID: 37301632
[TBL] [Abstract][Full Text] [Related]
95. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
Patel MR; Donnellan W; Byrne M; Asch AS; Zeidan AM; Baer MR; Fathi AT; Kuykendall AT; Zheng F; Walker C; Cheng L; Marando C; Savona MR
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):674-686. PubMed ID: 37290996
[TBL] [Abstract][Full Text] [Related]
96. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
97. A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Zeidan AM; Cook RJ; Bordoni R; Berenson JR; Edenfield WJ; Mohan S; Zhou G; Asatiani E; Srinivas N; Savona MR
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):523-534. PubMed ID: 35260349
[TBL] [Abstract][Full Text] [Related]
98. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Mazzacurati L; Collins RJ; Pandey G; Lambert-Showers QT; Amin NE; Zhang L; Stubbs MC; Epling-Burnette PK; Koblish HK; Reuther GW
Blood Adv; 2019 Nov; 3(22):3503-3514. PubMed ID: 31725895
[TBL] [Abstract][Full Text] [Related]
99. Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF.
Scherber RM; Mesa RA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):118-126. PubMed ID: 30504300
[TBL] [Abstract][Full Text] [Related]
100. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
